LCB84 vs Sacituzumab Govitecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
LCB84
Developed by Janssen and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT05089734 · Phase 3 · active, not recruiting
This was a randomized, open-label Phase 3 trial of 603 patients comparing sacituzumab govitecan to docetaxel, using overall survival (a hard clinical endpoint) as the primary measure. Although the drug showed a numerical survival advantage (11.1 vs 9.8 months), the difference did not reach statistical significance (p=0.0534), so the trial's primary comparison was not formally met despite a reasonably strong and adequately powered design.
Next expected readout: January 2027 · NCT05609968 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 24.4 months): EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant (missed)
Result source: NCT05089734
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | LCB84 | Sacituzumab Govitecan |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT05609968 |
| OS, median | —Not reported | —Trial running · NCT05609968 |
| ORR | —Not reported | —Trial running · NCT05609968 |
| Duration of response, median | —Not reported | —Trial running · NCT05609968 |
PFS, median
- LCB84
- —Not reported
- Sacituzumab Govitecan
- —Trial running · NCT05609968
OS, median
- LCB84
- —Not reported
- Sacituzumab Govitecan
- —Trial running · NCT05609968
ORR
- LCB84
- —Not reported
- Sacituzumab Govitecan
- —Trial running · NCT05609968
Duration of response, median
- LCB84
- —Not reported
- Sacituzumab Govitecan
- —Trial running · NCT05609968
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
LCB84: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. LCB84: 0 of 4 rows · Sacituzumab Govitecan: 1 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Sacituzumab Govitecan |
|---|---|
| Dropout rate | 4.8%10 mg/kga NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mg/kga NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | —10 mg/kga NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LCB84's landscape · Sacituzumab Govitecan's landscape